Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.pharmthera.2018.05.014 http://scihub22266oqcxt.onion/10.1016/j.pharmthera.2018.05.014 29859177!6192704!29859177     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacol+Ther 2018 ; 190 (ä): 128-138 Nephropedia Template TP {{tp|p=29859177|t=2018. Targeting phosphatases of regenerating liver (PRLs) in cancer |pdf=|usr=}}{{29859177}} gab.com Text Targeting phosphatases of regenerating liver (PRLs) in cancer JO: Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=29859177 #FOAvip The phosphatase of regenerating liver (PRL) family, also known as protein tyrosine phosphatase 4A (PTP4A), are dual-specificity phosphatases with largely unknown cellular functions. However, accumulating evidence indicates that PRLs are oncogenic across a broad variety of human cancers. PRLs are highly expressed in advanced tumors and metastases compared to early stage cancers or matched healthy tissue, and high expression of PRLs often correlates with poor patient prognosis. Consequentially, PRLs have been considered potential therapeutic targets in cancer. Persistent efforts have been made to define their role and mechanism in cancer progression and to create specific PRL inhibitors for basic research and drug development. However, targeting PRLs with small molecules remains challenging due to the highly conserved active site of protein tyrosine phosphatases and a high degree of sequence similarity between the PRL protein families. Here, we review the current PRL inhibitors, including the strategies used for their identification, their biological efficacy, potency, and selectivity, with a special focus on how PRL structure can inform future efforts to develop specific PRL inhibitors. Twit Text FOAVip Targeting phosphatases of regenerating liver (PRLs) in cancer ????Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=29859177 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29859177 #FOAvip English Wikipedia <ref>{{Cite pmid|29859177}}</ref> Targeting phosphatases of regenerating liver (PRLs) in cancer #MMPMID29859177 Wei M; Korotkov KV; Blackburn JS Pharmacol Ther 2018[Oct]; 190 (ä): 128-138 PMID29859177show ga The phosphatase of regenerating liver (PRL) family, also known as protein tyrosine phosphatase 4A (PTP4A), are dual-specificity phosphatases with largely unknown cellular functions. However, accumulating evidence indicates that PRLs are oncogenic across a broad variety of human cancers. PRLs are highly expressed in advanced tumors and metastases compared to early stage cancers or matched healthy tissue, and high expression of PRLs often correlates with poor patient prognosis. Consequentially, PRLs have been considered potential therapeutic targets in cancer. Persistent efforts have been made to define their role and mechanism in cancer progression and to create specific PRL inhibitors for basic research and drug development. However, targeting PRLs with small molecules remains challenging due to the highly conserved active site of protein tyrosine phosphatases and a high degree of sequence similarity between the PRL protein families. Here, we review the current PRL inhibitors, including the strategies used for their identification, their biological efficacy, potency, and selectivity, with a special focus on how PRL structure can inform future efforts to develop specific PRL inhibitors. |Animals[MESH] |Antineoplastic Agents/*pharmacology[MESH] |Disease Progression[MESH] |Drug Development/methods[MESH] |Humans[MESH] |Molecular Targeted Therapy[MESH] |Neoplasm Staging[MESH] |Neoplasms/drug therapy/enzymology/*pathology[MESH]Targeting phosphatases of regenerating liver (PRLs) in cancer (epmc).pdf DeepDyve Pubget Overpricing